Aurinia Announces Japan Approval Of LUPKYNIS To Treat Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the approval of its drug LUPKYNIS (voclosporin) by the Japanese Ministry of Health for treating lupus nephritis. This approval follows a successful clinical program and collaboration with Otsuka Pharmaceutical.
September 24, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals received Japanese approval for LUPKYNIS to treat lupus nephritis, potentially boosting its market presence and revenue.
The approval of LUPKYNIS in Japan is a significant regulatory milestone for Aurinia, likely to enhance its market presence and revenue potential. The collaboration with Otsuka Pharmaceutical and successful clinical trials underpin this positive development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100